Merck

Merck announced positive Phase 2 trial data for zilovertamab vedotin, an investigational antibody-drug conjugate targeting ROR1, in combination with...

Gilead Sciences and Merck have announced positive results from a Phase 2 clinical trial investigating a novel combination therapy...

Merck has acquired CN201, a bispecific antibody, from Curon Biopharmaceutical. This acquisition strengthens Merck’s pipeline for treating B-cell malignancies...

Japan’s Ministry of Health has approved new indications for KEYTRUDA (pembrolizumab) in treating certain lung and urothelial cancers. KEYTRUDA,...

The European Commission (EC) has granted approval to the combination of KEYTRUDA (pembrolizumab) and Padcev (enfortumab vedotin) as a...

Merck has discontinued two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630. The KEYNOTE-867 trial evaluated the combination of KEYTRUDA (pembrolizumab)...

Merck has launched Shorespan-007, a Phase 3 clinical trial evaluating bomedemstat for treating patients with essential thrombocythemia (ET) who...

Merck has announced the termination of the KeyVibe-008 Phase 3 trial evaluating the combination of vibostolimab and pembrolizumab in...

Merck (MSD outside the US and Canada) has acquired CN201, a novel bispecific antibody, from Curon Biopharmaceutical. CN201 targets...

The European Medicines Agency (EMA) has recommended approval of Merck’s KEYTRUDA and Padcev combination for the first-line treatment of...